India Makes Clinical Research Comeback But Challenges Remain
This article was originally published in PharmAsia News
Executive Summary
Recent steps by the Indian government to streamline procedures for clinical trials are bringing a new glimmer of hope to the beleaguered industry. An improved framework now exists that puts India in a better place than pre-2010, however it may take more collaborative efforts to align India with international norms, says Gopalkrishna Pai, General Manager, George Clinical (India).
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.